X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $132.74 | -5,500 | 177,873 | -3% | -$730,070 | |||||
| D | 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $114.97 | -77,109 | 244,883 | -24% | -$8,864,829 | |||||
2026-07-01 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | S - Sale | $114.29 | -3,389 | 47,179 | -7% | -$387,329 | ||||||
| D | 2026-07-01 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $115.29 | -80,000 | 666,568 | -11% | -$9,223,527 | |||||
| A | 2026-06-29 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $108.05 | -76,650 | 462,856 | -14% | -$8,281,905 | |||||
2026-07-01 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $76.71 | -1,625 | 42,044 | -4% | -$124,651 | ||||||
| D | 2026-07-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $29.90 | -14,609 | 0 | -100% | -$436,864 | |||||
2026-07-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $29.98 | -34,501 | 310,508 | -10% | -$1,034,253 | ||||||
2026-07-01 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $126.29 | -15,000 | 607,133 | -2% | -$1,894,400 | ||||||
2026-06-30 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $19.09 | -50,000 | 228,913 | -18% | -$954,500 | ||||||
| D | 2026-06-30 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $14.00 | -6,566 | 8,617 | -43% | -$91,924 | |||||
| D | 2026-07-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Former Director | S - Sale+OE | $10.41 | -9,599 | 138,855 | -6% | -$99,926 | |||||
2026-06-30 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $34.73 | -373 | 102,363 | 0% | -$12,954 | ||||||
| DM | 2026-06-29 | RGNX | Regenxbio Inc. | Pakola Steve | Chief Medical Officer | S - Sale+OE | $12.23 | -56,333 | 213,009 | -21% | -$688,756 | |||||
2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Tamayo Louis Edward | CFO | S - Sale | $4.49 | -4,641 | 97,024 | -5% | -$20,838 | ||||||
2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | COO | S - Sale | $4.48 | -4,666 | 137,482 | -3% | -$20,904 | ||||||
2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Bhalla Narinder Pal | Chief Medical Officer | S - Sale | $4.42 | -22,306 | 82,194 | -21% | -$98,593 | ||||||
2026-07-01 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $4.48 | -25,947 | 377,817 | -6% | -$116,243 | ||||||
| D | 2026-06-29 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $187.99 | -5,580 | 21,656 | -20% | -$1,048,967 | |||||
| D | 2026-06-30 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Chief Scientific Officer | S - Sale+OE | $35.00 | -172 | 55,285 | 0% | -$6,020 | |||||
| DM | 2026-06-29 | IBRX | Immunitybio, Inc. | Selecky Christobel | Dir | S - Sale+OE | $9.01 | -96,722 | 0 | -100% | -$871,216 | |||||
| D | 2026-06-30 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Chief Medical Officer | S - Sale+OE | $24.50 | -5,407 | 60,612 | -8% | -$132,472 | |||||
2026-06-30 | XFOR | X4 Pharmaceuticals, Inc | Kirske David | CFO | S - Sale | $4.26 | -8,543 | 167,750 | -5% | -$36,428 | ||||||
2026-06-29 | CADL | Candel Therapeutics, Inc. | Barone Francesca | Chief Scientific Officer | S - Sale | $10.06 | -23,447 | 77,362 | -23% | -$235,769 | ||||||
2026-06-29 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale | $10.02 | -7,000 | 83,865 | -8% | -$70,151 | ||||||
| D | 2026-06-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $28.02 | -7,500 | 26,250 | -22% | -$210,150 | |||||
| D | 2026-06-29 | TARA | Protara Therapeutics, Inc. | Shefferman Jesse | CEO, Pres | S - Sale+OE | $4.09 | -215,687 | 991,832 | -18% | -$882,160 | |||||
| DM | 2026-06-29 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $34.90 | -50,000 | 1,150,205 | -4% | -$1,745,037 | |||||
| DM | 2026-06-26 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Commercial Ofc Imm Med | S - Sale+OE | $21.13 | -165,802 | 221,278 | -43% | -$3,503,510 | |||||
2026-06-29 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $109.48 | -31,283 | 461,794 | -6% | -$3,424,800 | ||||||
| M | 2026-06-26 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $110.01 | -513,245 | 466,077 | -52% | -$56,460,136 | |||||
| D | 2026-06-29 | HALO | Halozyme Therapeutics, Inc. | Krishnan Mahesh | Dir | S - Sale+OE | $75.00 | -7,304 | 14,462 | -34% | -$547,800 | |||||
| DM | 2026-06-26 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $170.15 | -10,000 | 54,729 | -15% | -$1,701,492 | |||||
| D | 2026-06-29 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Chief Medical Officer | S - Sale+OE | $22.95 | -6,000 | 59,992 | -9% | -$137,700 | |||||
| D | 2026-06-29 | GLUE | Monte Rosa Therapeutics, Inc. | Manning Anthony M. | Dir | S - Sale+OE | $23.11 | -10,000 | 0 | -100% | -$231,100 | |||||
| D | 2026-06-26 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale+OE | $44.90 | -2,732 | 886 | -76% | -$122,667 | |||||
2026-06-26 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | CFO | S - Sale | $44.75 | -5,000 | 16,009 | -24% | -$223,750 | ||||||
| D | 2026-06-26 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $45.00 | -10,000 | 75,753 | -12% | -$450,000 | |||||
| D | 2026-06-26 | VCEL | Vericel Corp | Flynn Sean C. | GC | S - Sale+OE | $45.64 | -15,000 | 1,647 | -90% | -$684,600 | |||||
2026-06-25 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $20.50 | -5,000 | 406,775 | -1% | -$102,500 | ||||||
| D | 2026-06-25 | ADPT | Adaptive Biotechnologies Corp | Griffin Michelle Renee | Dir | S - Sale+OE | $20.18 | -52,084 | 15,625 | -77% | -$1,051,055 | |||||
2026-06-25 | CGON | Cg Oncology, Inc. | Liu Brian Guan-Chyun | Dir | P - Purchase | $66.87 | +371,085 | 1,886,236 | +24% | +$24,814,454 | ||||||
2026-06-25 | PASG | Passage Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $4.12 | +50,055 | 673,759 | +8% | +$206,101 | ||||||
| M | 2026-06-25 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $8.89 | +32,876 | 17,955,642 | 0% | +$292,126 | |||||
| M | 2026-06-25 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $6.40 | +152,533 | 2,895,107 | +6% | +$976,490 | |||||
| M | 2026-06-25 | BEAM | Beam Therapeutics Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $35.24 | -284,860 | 1,695,828 | -14% | -$10,039,492 | |||||
2026-06-24 | IBRX | Immunitybio, Inc. | Simon Barry J. | Dir | S - Sale | $7.88 | -25,000 | 2,802,788 | -1% | -$196,908 | ||||||
2026-06-26 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $38.31 | -17,714 | 224,393 | -7% | -$678,604 | ||||||
2026-06-26 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $38.31 | -40,000 | 211,685 | -16% | -$1,532,309 | ||||||
| D | 2026-06-26 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale+OE | $38.31 | -17,824 | 180,597 | -9% | -$682,887 | |||||
| D | 2026-06-26 | IMVT | Immunovant, Inc. | Girao Tiago | CFO | S - Sale+OE | $38.46 | -10,000 | 247,596 | -4% | -$384,600 | |||||
| D | 2026-06-26 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $38.01 | -1,500 | 136,731 | -1% | -$57,015 | |||||
2026-06-26 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale | $55.22 | -24,237 | 586,681 | -4% | -$1,338,270 | ||||||
| D | 2026-06-25 | KRYS | Krystal Biotech, Inc. | Thomas John Charles | EVP, GC | S - Sale+OE | $347.27 | -1,000 | 0 | -100% | -$347,270 | |||||
| D | 2026-06-25 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $95.00 | -18,880 | 824,039 | -2% | -$1,793,600 | |||||
2026-06-25 | GRML | Greenland Mines Ltd | El-Dada Riad Hussein | Dir | S - Sale | $0.23 | -175,000 | 175,000 | -50% | -$40,548 | ||||||
| D | 2026-06-24 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $168.33 | -20,000 | 123,269 | -14% | -$3,366,604 | |||||
2026-06-24 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $89.75 | -14,205 | 105,141 | -12% | -$1,274,899 | ||||||
2026-06-25 | RGEN | Repligen Corp | Garland Jason K | CFO | S - Sale | $145.00 | -733 | 19,359 | -4% | -$106,285 | ||||||
2026-06-25 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $121.86 | -285,684 | 529,718 | -35% | -$34,812,909 | ||||||
| M | 2026-06-23 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $110.31 | -398,765 | 564,668 | -41% | -$43,987,355 | |||||
| D | 2026-06-25 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | S - Sale+OE | $114.00 | -5,000 | 50,195 | -9% | -$570,000 | |||||
| D | 2026-06-23 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $12.00 | -9,810 | 8,617 | -53% | -$117,720 | |||||
| D | 2026-06-24 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $70.00 | -5,000 | 0 | -100% | -$350,000 | |||||
| DM | 2026-06-23 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Chief Medical Officer | S - Sale+OE | $21.08 | -41,845 | 59,992 | -41% | -$882,203 | |||||
| D | 2026-06-23 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $20.00 | -2,175 | 62,371 | -3% | -$43,500 | |||||
| D | 2026-06-23 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | S - Sale+OE | $20.00 | -3,000 | 67,845 | -4% | -$60,000 | |||||
2026-06-22 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $132.60 | -26,400 | 179,248 | -13% | -$3,500,640 | ||||||
2026-06-22 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $132.54 | -80,000 | 1,015,987 | -7% | -$10,603,200 | ||||||
| M | 2026-06-22 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $0.95 | +109,200 | 823,475 | +15% | +$103,584 | |||||
| M | 2026-06-22 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.04 | -27,858 | 345,009 | -7% | -$725,495 | |||||
| D | 2026-06-22 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale+OE | $16.97 | -187,163 | 177,461 | -51% | -$3,176,865 | |||||
| D | 2026-06-22 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale+OE | $16.94 | -93,456 | 418,557 | -18% | -$1,583,145 | |||||
2026-06-22 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $87.32 | -291 | 120,414 | 0% | -$25,411 | ||||||
2026-06-22 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $87.32 | -346 | 119,346 | 0% | -$30,214 | ||||||
| D | 2026-06-22 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $87.32 | -1,688 | 842,919 | 0% | -$147,400 | |||||
| D | 2026-06-22 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $65.00 | -5,000 | 0 | -100% | -$325,000 | |||||
2026-06-22 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $10.47 | -114,746 | 942,485 | -11% | -$1,200,851 | ||||||
2026-06-22 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $103.75 | -31,798 | 613,762 | -5% | -$3,299,037 | ||||||
| DM | 2026-06-17 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale+OE | $94.72 | -478,198 | 617,663 | -44% | -$45,293,294 | |||||
| D | 2026-06-22 | KYMR | Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | S - Sale+OE | $99.00 | -2,500 | 50,195 | -5% | -$247,500 | |||||
2026-06-18 | RXRX | Recursion Pharmaceuticals, Inc. | Bumpus Namandje | Dir | S - Sale | $3.18 | -3,963 | 127,632 | -3% | -$12,602 | ||||||
2026-06-17 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $61.55 | -10,000 | 881,412 | -1% | -$615,488 | ||||||
| D | 2026-06-18 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $40.24 | -10,000 | 16,248 | -38% | -$402,400 | |||||
| D | 2026-06-18 | VCEL | Vericel Corp | Flynn Sean C. | GC | S - Sale+OE | $40.21 | -15,000 | 1,647 | -90% | -$603,150 | |||||
2026-06-18 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $35.39 | -2,634 | 180,597 | -1% | -$93,217 | ||||||
2026-06-18 | CRDF | Cardiff Oncology, Inc. | Mohindru Mani | CEO | P - Purchase | $1.21 | +24,703 | 24,703 | New | +$29,891 | ||||||
2026-06-18 | CRDF | Cardiff Oncology, Inc. | Pace Gary W | Dir | P - Purchase | $1.22 | +30,000 | 1,356,376 | +2% | +$36,600 | ||||||
| M | 2026-06-17 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.89 | +2,300 | 300,566 | +1% | +$2,043 | |||||
| D | 2026-06-18 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $52.50 | -24,461 | 609,918 | -4% | -$1,284,205 | |||||
| D | 2026-06-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $53.00 | -10,000 | 166,245 | -6% | -$530,000 | |||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale | $156.12 | -4,615 | 49,975 | -8% | -$720,490 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $156.12 | -10,020 | 990,238 | -1% | -$1,564,310 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $156.12 | -2,157 | 56,521 | -4% | -$336,749 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $156.12 | -2,722 | 123,269 | -2% | -$424,956 | ||||||
2026-06-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $156.12 | -4,175 | 291,876 | -1% | -$651,798 | ||||||
| D | 2026-06-17 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $19.00 | -2,176 | 62,371 | -3% | -$41,344 | |||||
| D | 2026-06-17 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | S - Sale+OE | $19.00 | -3,000 | 67,845 | -4% | -$57,000 | |||||
| M | 2026-06-15 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $17.41 | -106,160 | 1,405,898 | -7% | -$1,847,942 | |||||
| DM | 2026-06-15 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $160.00 | -93,575 | 154,647 | -38% | -$14,972,110 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |